News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amneal Pharmaceuticals Launches Felbamate Oral Suspension



12/22/2011 6:53:31 AM

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, LLC is pleased to announce availability of the first generic Felbamate oral suspension in 600 mg/5 mL strength. Amneal’s newest first-to-market product is an AB-rated, therapeutically equivalent alternative to the antiepileptic Felbatol® (a registered trademark of Meda Pharmaceuticals Inc.). Annual U.S. sales of Felbatol® are $17.6 million according to June 2011 IMS Health market data. Amneal received ANDA approval for Felbamate oral suspension from the U.S. FDA on December 16, 2011.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES